ArticleInternational journal of inflammation2012
Pharmacological Evaluation of the SCID T Cell Transfer Model of Colitis: As a Model of Crohn's Disease.
Article in International journal of inflammation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Selective SIK2/SIK3 inhibition reprograms pro- and antiinflammatory pathways in myeloid cells, improving autoimmune disease outcomes.JCI insight · 2026Article
- Effects of CCL20/CCR6 Modulators in a T Cell Adoptive Transfer Model of Colitis.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Immunopathological and microbial signatures of inflammatory bowel disease in partial RAG deficiency.The Journal of experimental medicine · 2025Article
- Effect of Integrin Blockade on Experimental Spondyloarthritis.Biomolecules · 2024Article
- A Structured Approach to Optimizing Animal Model Selection for Human Translation: The Animal Model Quality Assessment.ILAR journal · 2021Article
- Oral administration of D-serine prevents the onset and progression of colitis in mice.Journal of gastroenterology · 2021Article
- Nephroprotective Potential of Mesenchymal Stromal Cells and Their Extracellular Vesicles in a Murine Model of Chronic Cyclosporine Nephrotoxicity.Frontiers in cell and developmental biology · 2020Article
- REV-ERBα Regulates TCell reports · 2018Article
- Obstructive Lymphangitis Precedes Colitis in Murine Norovirus-Infected Stat1-Deficient Mice.The American journal of pathology · 2018Article
- Evaluating IL-21 as a Potential Therapeutic Target in Crohn's Disease.Gastroenterology research and practice · 2018Article
- Acute severe ulcerative colitis: from pathophysiology to clinical management.Nature reviews. Gastroenterology & hepatology · 2016Review
- Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1 ) and receptor-5 (S1P5 ) agonist with autoimmune disease-modifying activity.British journal of pharmacology · 2016Article
- Galectin-3 suppresses mucosal inflammation and reduces disease severity in experimental colitis.Journal of molecular medicine (Berlin, Germany) · 2016Article
- The Intersection of TNF, IBD and the Microbiome.Gut microbes · 2016Article
- Treatment with a Monoclonal Anti-IL-12p40 Antibody Induces Substantial Gut Microbiota Changes in an Experimental Colitis Model.Gastroenterology research and practice · 2016Article
- Protective Role of β-arrestin2 in Colitis Through Modulation of T-cell Activation.Inflammatory bowel diseases · 2015Article
- Anti-inflammatory effects of the Chinese herbal formula FAHF-2 in experimental and human IBD.Inflammatory bowel diseases · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Animal models are important tools in the development of new drug candidates against the inflammatory bowel diseases (IBDs) Crohn's disease and ulcerative colitis. In order to increase the translational value of these models, it is important to increase knowledge relating to standard drugs. Using the SCID adoptive transfer colitis model, we have evaluated the effect of currently used IBD drugs and IBD drug candidates, that is, anti-TNF-α, TNFR-Fc, anti-IL-12p40, anti-IL-6, CTLA4-Ig, anti-α4β7 integrin, enrofloxacin/metronidazole, and cyclosporine. We found that anti-TNF-α, antibiotics, anti-IL-12p40, anti-α4β7 integrin, CTLA4-Ig, and anti-IL-6 effectively prevented onset of colitis, whereas TNFR-Fc and cyclosporine did not. In intervention studies, antibiotics, anti-IL-12p40, and CTLA4-Ig induced remission, whereas the other compounds did not. The data suggest that the adoptive transfer model and the inflammatory bowel diseases have some main inflammatory pathways in common. The finding that some well-established IBD therapeutics do not have any effect in the model highlights important differences between the experimental model and the human disease.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.